← Back to Search

Glycopeptide Antibiotic

Oritavancin for Bacterial Infections in Children

Phase 1
Recruiting
Research Sponsored by Melinta Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females <18 years of age
Suspected or diagnosed Gram positive bacterial infection for which the subject is receiving standard antibiotic therapy; or peri-operative prophylactic use of antibiotics
Must not have
Females who are of childbearing potential and unwilling to practice abstinence or use at least two methods of contraception or female patients of childbearing who are lactating or have a positive pregnancy test result at screening
Males who are unwilling to practice abstinence or use an acceptable method of birth control during the entire study period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 336 hours post infusion start time for cohorts 1-4 and 168 hours for cohort 5
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug to see if it is safe and effective in children with a bacterial infection.

Who is the study for?
This trial is for children under 18 with suspected or confirmed Gram-positive bacterial infections. Neonates must be at least 34 weeks post-conception age. Participants need IV access and will stay in the hospital for observation after receiving the drug. Those with septic shock, hypersensitivity to similar drugs, recent use of certain antibiotics, or females who are pregnant/lactating or not using contraception are excluded.
What is being tested?
The study tests Oritavancin's effects on pediatric patients with bacterial infections. It aims to understand how the body processes this drug (pharmacokinetics), its safety, and tolerability when given to kids and teenagers as either a treatment for infection or as a preventive measure during surgery.
What are the potential side effects?
While specific side effects in children aren't detailed here, Oritavancin may cause symptoms like allergic reactions, gastrointestinal issues (nausea/vomiting), skin reactions at injection site, liver enzyme changes, blood clotting problems and possibly others similar to adults.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am under 18 years old.
Select...
I am currently being treated with antibiotics for a suspected or confirmed Gram positive bacterial infection.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am a woman able to have children and will use two forms of birth control or abstain.
Select...
I agree to use birth control or practice abstinence during the study.
Select...
I haven't taken certain antibiotics recently and don't plan to take them soon.
Select...
I haven't used any experimental drugs or devices recently.
Select...
I am currently experiencing severe infection or sudden blood pressure drops.
Select...
I do not have any major organ system diseases.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~336 hours post infusion start time for cohorts 1-4 and 168 hours for cohort 5
This trial's timeline: 3 weeks for screening, Varies for treatment, and 336 hours post infusion start time for cohorts 1-4 and 168 hours for cohort 5 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pharmacokinetic Parameter (Area under the plasma concentration time-curve [AUC])
Secondary study objectives
Pharmacokinetic Parameters
Safety Endpoint

Side effects data

From 2016 Phase 4 trial • 17 Patients • NCT02452918
50%
Nausea
50%
Infusion site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Oritavancin 1200 mg With Concomitant Warfarin Therapy
Oritavancin 1200 mg Without Concomitant Warfarin Therapy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: OritavancinExperimental Treatment1 Intervention
Single-Dose IV Oritavancin Diphosphate
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oritavancin
2015
Completed Phase 4
~460

Find a Location

Who is running the clinical trial?

Melinta Therapeutics, LLCLead Sponsor
2 Previous Clinical Trials
208 Total Patients Enrolled
Melinta Therapeutics, Inc.Lead Sponsor
35 Previous Clinical Trials
9,507 Total Patients Enrolled
Karen FusaroStudy DirectorMelinta Therapeutics, Inc.
4 Previous Clinical Trials
906 Total Patients Enrolled

Media Library

Oritavancin (Glycopeptide Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT02134301 — Phase 1
Staph Infection Research Study Groups: Oritavancin
Staph Infection Clinical Trial 2023: Oritavancin Highlights & Side Effects. Trial Name: NCT02134301 — Phase 1
Oritavancin (Glycopeptide Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02134301 — Phase 1
~4 spots leftby Dec 2025